Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether
motesanib improved progression-free survival (PFS) compared with placebo in combination with
paclitaxel and
carboplatin (P/C) in East Asian patients with stage IV/recurrent nonsquamous
non-small-cell lung cancer. Patients and Methods Patients were randomly assigned (1:1) to receive oral
motesanib 125 mg or placebo once daily plus
paclitaxel 200 mg/m2 IV and
carboplatin area under the concentration-time curve 6 mg/mL ⋅ min IV for up to six 3-week cycles. Random assignment was stratified by
epidermal growth factor receptor status, region, and
weight loss in the 6 months before assignment. The primary end point was PFS, the key secondary end point was overall survival, and other secondary end points were objective response rate, time to
tumor response, duration of response, and adverse events (AEs). Results Four hundred one patients were assigned to receive
motesanib plus P/C (n = 197) or placebo plus P/C (n = 204). Median PFS was 6.1 v 5.6 months for
motesanib versus placebo (stratified log-rank test P = .0825; stratified hazard ratio, 0.81; 95% CI, 0.64 to 1.03; P = .0820); median overall survival was not reached versus 21.6 months ( P = .5514). In secondary analyses, the objective response rate was 60.1% v 41.6% ( P < .001); median time to
tumor response, 1.4 v 1.6 months, and median duration of response, 5.3 v 4.1 months. Incidence of grade ≥ 3 AEs (86.7% v 67.6%) and AEs that led to
drug discontinuation (32.7% v 14.2%) were higher with
motesanib than with placebo. AEs reported more frequently with
motesanib were GI disorders,
hypertension, and gallbladder related. Conclusion
Motesanib plus P/C did not significantly improve PFS versus placebo plus P/C in East Asian patients with stage IV/recurrent nonsquamous
non-small-cell lung cancer.